Article: Lundbeck to market Neurim insomnia treatment: The treatment, based on prolonged release Melatonin, is approved in Europe.

Byline: Gali Weinreb

Sep. 25--Neurim Pharmaceuticals Ltd. has granted Danish pharmaceutical company H. Lundbeck A/S (KFX:LUN) a license for exclusive rights to market its Circadin treatment of primary insomnia in the majority of European markets, including the UK, Germany, France, Spain, and Poland. Lundbeck was also granted an exclusive option to evaluate commercialization in markets outside of Europe. Lundbeck said that it expected to launch Circadin in the first markets during 2008.

Neurim declined to disclose the size of the deal, but said that it "receives an upfront payment and a share of revenue. Neurim is responsible for manufacturing."

A rough estimate on ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!